Skip to main content
Clinical Trials/NL-OMON55975
NL-OMON55975
Recruiting
Phase 3

Effectiveness of focal therapy in men with prostate cancer (ENFORCE) - ENFORCE

Radboud Universitair Medisch Centrum0 sites356 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Prostate carcinoma
Sponsor
Radboud Universitair Medisch Centrum
Enrollment
356
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Men with unilateral clinically significant intermediate\-risk PCa ór dominant
  • unilateral clinically significant intermediate\-risk and small contralateral
  • low\-risk (ISUP 1\) disease:
  • Gleason score of 7 (3 \+ 4 or 4 \+ 3; ISUP grade 2/3\)
  • PSA level of \<\= 20 ng/ml
  • Clinical stage \<\= T2b disease
  • Life expectancy of \>\= 10 years
  • Men with a prostate size \<\= 5 cm in sagittal length and \<\= 6 cm in axial length
  • Fit, eligible, and normally destined for radical surgery or radiotherapy
  • No concomitant cancer

Exclusion Criteria

  • A potential subject who meets any of the following criteria will be excluded
  • from participation in this study: • Unfit for general anesthesia or radical
  • surgery • Low volume low\-risk disease (\<\=4mmGleason score of \<\= 6 / ISUP grade 1\)
  • High\-risk disease (Gleason score of \>\= 8 / ISUP grade \>3\) • Clinical T3
  • disease (extracapsular PCa) • Men who have received previous active therapy for
  • PCa. • Men with evidence of extraprostatic disease. • Men with an inability to
  • tolerate a transrectal ultrasound. • Cardiac pacemaker • Metal implants/stents
  • in the urethra or prostate. • ASA \>\=4 • Prostatic calcification/cysts that
  • interfere with effective delivery of TULSA/HIFU based on CT. • Men with renal
  • impairment and a glomerular filtration rate (GFR) of \< 30 ml/minute/1\.73 m2\. •

Outcomes

Primary Outcomes

Not specified

Similar Trials